共查询到20条相似文献,搜索用时 13 毫秒
1.
E. Garcia-Giralt Y. Ayme M. Carton A. Daban T. Delozier P. Fargeot P. Fumoleau A. Gorins D. Guerin R. Guerin P. Maillart L. Mauriac F. May-Levin R. Metz M. Namer J. P. Olivier E. Pommatau P. Pouillart E. Pujade-Lauraine J. Rouesse B. Serrou M. Vitse D. Zylberait 《Breast cancer research and treatment》1992,21(2):139-145
Summary In order to evaluate the efficacy of two different sequences of second and third line hormonotherapy in advanced post-menopausal breast cancer, 257 women aged 36–91 years (mean age: 63.6 years) who had become resistant to tamoxifen (TAM), entered into a multicenter randomized trial comparing two different regimens: 1) Aminoglutethimide (Ag) 500 mg/day with hydrocortisone supplementation from 30 to 60 mg/day; and 2) oral medroxyprogesterone acetate (MPA) 500 mg twice a day.250 patients were evaluated following second line hormone therapy and, after cross-over, 128 following third line hormonotherapy.No significant difference was observed, during either second or third line therapies, for toxicity, survival, or response rate; however, in both second and third line therapies the median time to progression was significantly longer with Ag therapy. 相似文献
2.
R. J. Santen M.D. 《Breast cancer research and treatment》1981,1(3):183-202
Summary Fifty to sixty percent of postmenopausal women with estrogen receptor positive metastatic breast cancer respond objectively to surgical ablation of the pituitary or adrenal glands. Several investigators have recently developed medical alternatives to surgical ablative therapy for these patients. This review describes one of these strategies, the inhibition of estrogen synthesis with the enzyme inhibitor aminoglutethimide (AG). Aminoglutethimide blocks several cytochrome P-450-mediated steroid hydroxylation steps including those required for cholesterol to pregnenolone conversion and for the aromatization of androgens to estrogens. In women with metastatic carcinoma, a regimen including 1,000 mg of AG and 40 mg of hydrocortisone as replacement glucocorticoid was administered daily. Clinical studies revealed a 32% objective response rate to AG-HC in unselected patients, and a 52% response in women with estrogen receptor positive tumors. Randomized trials revealed that AG-HC produced objective regression as frequently as surgical adrenalectomy (Ag-HC + 53% vs. surgical adrenalectomy (43%,p = NS), and as surgical hypophysectomy (AG-HC 47% vs. hypox 21%,p + NS). Comparison of AG-HC administration with antiestrogen treatment suggested an equal rate of response to either therapy. Preliminary data document responses to AG in antiestrogen-resistant patients. Current studies do not allow precise recommendations regarding the sequence of use of antiestrogens and AG-HC.
Address for reprints: Richard J. Santen, M.D., Division of Endocrinology. The Milton S. Hershey Medical Center, Hershey, PA 17033. 相似文献
3.
Seppo Pyrhönen Ritva Valavaara Jouni Vuorinen Alajos Hajba 《Breast cancer research and treatment》1994,29(3):223-228
Summary Fifty patients with advanced breast cancer refractory to prior tamoxifen therapy were assigned to investigational treatment with high-dose toremifene administered 120 mg orally twice a day. Treatment was generally well tolerated. The majority (80%) of the patients had no side effects, and among the remaining 10 patients reported side effects were mostly mild and/or transient. Two objective tumor responses were observed: one complete response (CR), duration 6.2 months, and one partial response (PR), duration 8 months. The response rate was thus 4% (95% CI: 0.5 to 14%). In addition 3 patients experienced a mixed response, some metastatic sites responding, while at other sites disease progressed; 22 patients had disease stabilization for > 2 months. A subset analysis disclosed that a small subgroup of patients, including 7 patients in this study, who had achieved CR at some of the sites during preceding tamoxifen therapy, experienced a long progressionfree time during high dose toremifene treatment. The median time to progression in this subgroup of patients was 9.4 months (95% CI: 3.8 to 9.4) as opposed to 2.1 months (95% CI: 2.0 to 2.8) for all the remaining 43 patients, which is a significant decrease in disease progression (p < 0.03). Such results reveal that although this kind of second-line hormonal treatment with high dose toremifene cannot be recommended for all tamoxifen failures, there might be a subset of patients, i.e. those who achieve CR in some lesion during tamoxifen therapy, who benefit from this type of treatment. 相似文献
4.
Rose C Kamby C Mouridsen HT Andersson M Bastholt L Møller KA Andersen J Munkholm P Dombernowsky P Christensen IJ 《Breast cancer research and treatment》2000,61(2):103-110
The efficacy of combined endocrine therapy with tamoxifen (TAM), aminoglutethimide (AG), and hydrocortisone (H) or tamoxifen and fluoxymesterone (FLU) was evaluated against treatment with tamoxifen alone in 311 patients above 65 years of age with a first recurrence of a metastatic breast cancer. A total of 279 patients were eligible. The response rates were assessed for 258 fully evaluable patients and were the following for the TAM (N=94), the TAM+AG+H (N=83), and the TAM+FLU (N=81) groups, respectively, PR: 14, 18, and 21%, and CR: 20, 11, and 23%. The overall response rates are not statistically different (p=0.30). The 95% CL of difference in response rates for TAM vs. TAM+AG+H are –9–19% and for TAM vs. TAM+FLU –4–25%. Time to treatment failure was comparable with median values of 9.2, 7.7, and 9.2 months in the TAM, TAM+AG+H, and TAM+FLU group, respectively (p=0.17). The corresponding figures for survival are median times of 22.0, 24.1, and 21.1 months with a p-value of 0.62. Toxicity was more pronounced in both the combined treatment groups, and could in most instances be attributed to treatment with either AG+H or FLU. Currently, new specific aromatase inhibitors with lesser toxicity than AG are being evaluated in combination with TAM for treatment of primary and metastatic breast cancer. In conclusion, the simultaneous use of TAM and AG+H or FLU does not seem to improve the therapeutic efficacy in elderly postmenopausal patients with metastatic disease. So far, combined endocrine therapy in this group of patients should only be used in the context of clinical trials. 相似文献
5.
6.
Richard J. Santen M.D. Elliott Badder M.D. Sheldon Lerman M.D. Harold Harvey M.B.B. Chr. Allan Lipton M.D. Alice E. Boucher Andrea Manni M.D. Howard Rosen B.S. Samuel A. Wells M.D. 《Breast cancer research and treatment》1982,2(4):375-383
Summary Recent studies suggest that estrogens are the predominant hormones required for the growth of hormonedependent breast cancers in women. Traditional methods of lowering estrogens as treatment of breast cancer involve surgical removal of the ovaries, adrenals, or pituitary. Newer investigative strategies utilize blockade of estrogen action with antiestrogens or inhibition of estrogen synthesis. As reviewed previously, a regimen for pharmacologic suppression of estrogen production was developed which utilizes the aromatase/steroidogenesis inhibitor aminoglutethimide (AG) and replacement hydrocortisone (HC). The current paper updates recent mechanistic, clinical, and hormonal data regarding AG.The preservation of plasma androstenedione levels concomitant with marked estrone and estradiol suppression suggests that AG lowers estrogen production predominantly by blocking aromatization. The mechanism for sustained androstenedione production in the face of suppressed ketosteroids, glucocorticoids, and mineralocorticoids during AG administration was evaluated in dogs fitted with arteriovenous adrenal cannulae. Inhibition of the adrenal secretion of androstenedione with preservation of peripheral plasma levels of this steroid suggests stimulation ofextra-adrenal 3-ol-dehydrogenase,
5-
4-isomerase activity by AG.Clinical studies revealed a 32% objective response rate to AG/HC in unselected patients and a 52% response in women with estrogen receptor positive tumors. Randomized trials indicated similar response rates to AG/HC vs hypophysectomy (AG/HC 47% vs Hypox 21%,p = NS), surgical adrenalectomy (AG/HC 52% vs surgical adrenalectomy 43%,p = NS) and antiestrogen therapy (AG/HC 36% vs tamoxifen 38%,p = NS). Cross-over data revealed that 50% of 94 patients initially responding to tamoxifen later experienced an objective regression to AG/HC. Only 25% of 93 tamoxifen nonresponders benefited later from AG/HC. Trends indicate that bone metastases may respond better to AG/HC (33%) than to tamoxifen (15%).Use of a computer-based data matrix allowed determination of whether patients escape from AG/HC induced estrogen and androgen suppression at the time of disease relapse. No trends towards escape from estrogen inhibition were apparent. However, in the objective responders to AG/HC, the weak androgens dehydroepiandrosterone-sulfate (DHEA-S) and androstenedione appeared to increase prior to disease relapse. DHEA-S but not androstenedione levels remained lower in the objective responders than in nonresponders at all phases of AG/HC therapy. Thus, the estrogens, but not androgens, remain constant during all phases of AG/HC treatment. 相似文献
7.
Summary Clinical results of tamoxifen (Nolvadex-ICI) monotherapy in 44 premenopausal women with advanced breast cancer have been reviewed. Objective tumor regression was achieved in 12 (27%) patients and a further 10 (22%) were classified as stabilized. Median duration of response was 12.7 months at the time of analysis. Greatest benefits occurred in soft tissue dominant and receptor-positive tumors, but there was no correlation between tumor response and other clinical manifestations of estrogen deprivation (e.g. menstrual disturbance, hot flushes).The benefits of conventional doses of tamoxifen do not therefore appear to be influenced by menopausal status and compare favorably to achievements reported after surgical oophorectomy. 相似文献
8.
Erkki Heinonen Arto Alanko Pentti Gröhn Pentti Rissanen 《Breast cancer research and treatment》1985,5(1):75-80
Summary Since 1980 we have been carrying out a prospective randomized trial comparing tamoxifen with the combination of tamoxifen plus nandrolone decanoate in advanced breast cancer. The tamoxifen dose is 30 mg daily and the nandrolone decanoate dose 100 mg i.m. once a week for four weeks and thereafter every other week. 98 post-menopausal patients have been evaluated for the response. The number of patients is 49 in both groups.The overall response rates (CR +PR) to tamoxifen and tamoxifen plus nandrolone decanoate were not significantly different; in the tamoxifen group the response rate was 49% and in the combination group 45%. The mean time to progression in tamoxifen group is over 13 months and in tamoxifen plus nandrolone decanoate group over 12 months. Our results do not suggest a synergistic effect from combining tamoxifen and nandrolone decanoate treatments. The response rates to tamoxifen at different sites of metastases were as follows: bones 47%, soft tissues 56%, and viscera 48%. The respective figures with the combination therapy were 36%, 64%, and 40%.Both treatments were well tolerated and in no patient was withdrawal of the therapy necessary. Mild virilization and hoarseness were experienced by all patients treated with nandrolone decanoate. Side-effects associated with tamoxifen were rare, although five patients experienced nausea and two had hot flushes. 相似文献
9.
《Expert review of anticancer therapy》2013,13(3):445-453
Fulvestrant is a new type of estrogen receptor antagonist with no agonist effects, and represents a valuable addition to the range of endocrine treatments available to treat postmenopausal women with advanced breast cancer. Fulvestrant binds, blocks and degrades the estrogen receptor, thereby retarding growth and progression of hormone-sensitive tumors. Two Phase III trials have demonstrated that fulvestrant is at least as effective as the third-generation aromatase inhibitor anastrozole in the treatment of advanced breast cancer following progression on antiestrogen therapy. In addition, a Phase III trial comparing fulvestrant with tamoxifen in postmenopausal women with advanced breast cancer showed similar efficacy and tolerability. Clinical trials are ongoing to evaluate different endocrine sequence options for postmenopausal women with breast cancer, and to evaluate the efficacy of fulvestrant in combination with anticancer agents that target other signaling pathways. 相似文献
10.
乳腺癌患者应用三苯氧胺导致的妇科并发症及其监测 总被引:1,自引:0,他引:1
三苯氧胺具有抗雌激素和雌激素的双重特性,长期持续使用可导致子宫内膜发生多种病理改变。临床应予以重视,并加以监测。本文就妇科并发症的发生和临床监测方面做一综述,以早发现、并减少并发症的发生。 相似文献
11.
Christian Peters‐Engl Wilhelm Frank Eberhard Danmayr Hans P. Friedl Sepp Leodolter Michael Medl 《Breast cancer research and treatment》1999,54(3):255-260
A retrospective cohortstudy in 4109 breast cancer patients was undertaken to determine how tamoxifen affected the risk of endometrial cancer. Data on 1701 tamoxifentreated women were analysed. Two thousand four hundred and eight nontamoxifen users served as control group. The occurrence of new primary uterine cancers was assessed by computerized linkage to the Austrian Cancer Registry. Twentyfive women who subsequently developed endometrial cancer were identified. Eight uterine cancers occurred in the tamoxifen group, whereas 17 uterine cancers were found in the control group. The estimate of the relative risk (RR) showed an increased risk to develop endometrial cancer for the tamoxifen group RR 1.136 (95% CI 0.71; 1.80). Analysis of relevant confounding variables did not show any differences in the two groups.In conclusion, this retrospective study demonstrated a nonsignificant increased risk of endometrial cancer in women receiving tamoxifen as treatment for breast cancer. However, the magnitude of RR and the absolute number of endometrial cancer cases in this long term observation demonstrate clearly that the clinical benefit of tamoxifen therapy greatly outweighs the risk. 相似文献
12.
L. Bergman J. A. van Dongen B. van Ooijen F. E. van Leeuwen 《Breast cancer research and treatment》1995,34(1):77-83
Summary To determine the efficacy of tamoxifen as primary treatment for elderly breast cancer patients with locoregional disease, the medical records of 85 patients of 75 years and older were reviewed. The median follow-up was 28 months (range 3–97 mo). Complete remission occurred in twelve (14.1%) patients. All of these patients remained in remission until death or closing date of the study. Twenty (23.5%) patients responded with a partial remission; 5 of them subsequently developed tumor progression. Thirteen (15.3%) patients developed initial tumor progression and 39 (45.9%) had disease stabilisation. Nineteen of this latter group subsequently developed tumor progression. Out of 37 (43.5%) patients with tumor progression, 14 patients were salvaged by surgery (n = 13) or radiotherapy (n = 1). Until the closing date of the study, disease could not be controlled by secondary treatment in 12 patients who subsequently died of breast cancer. Twenty-two of the 37 patients were unfit for surgical treatment at progression, of whom 14 were operable at diagnosis. The actuarial 5-year observed survival rate was 40% for the whole patient group.Conclusions: Although some patients (14.1%) managed to maintain a long lasting complete remission, caution should be preserved in using tamoxifen as first-line treatment, because of the high risk of treatment failures. As long as factors can not be identified to predict which subgroups of patients will respond to tamoxifen with a remission lasting for their life-time, tamoxifen may only provide an acceptable alternative for elderly breast cancer patients who are too frail or are unwilling to undergo surgery or radiotherapy. For elderly patients in good physical condition, primary treatment by tamoxifen only delays definitive surgical treatment. 相似文献
13.
Summary One hundred and twelve post menopausal or post oophorectomy women with advanced breast cancer (BC) who had all previously had aminoglutethimide (AG) were treated with the potent aromatase inhibitor 4-hydroxy androstenedione (4-OHA).Twenty three women (21%) had a partial response to 4-OHA while another twenty five patients (22%) had stabilization of previously progressing disease. Patients responded to 4-OHA both after previously responding to then relapsing on, and after failing to respond to aminoglutethimide. Toxicity was minimal. This study shows that potent aromatase inhibition with 4-OHA is effective in women with advanced BC who have already been treated with a less potent aromatase inhibitor, and suggests that relative changes in oestrogen levels may be more important than absolute levels. 相似文献
14.
D.U. BOEHM md resident of breast cancer centre A. LEBRECHT md leading consultant of breast cancer centre T. ECKHARDT doctoral student of university of halle S. ALBRICH md resident of breast cancer centre M. SCHMIDT md head of chemotherapy department W. SIGGELKOW md senior consultant of breast cancer centre E. KANDELHARDT md resident of breast cancer centre & H. KOELBL md director of 《European journal of cancer care》2009,18(5):500-506
About two-thirds of all breast cancer patients are treated with adjuvant hormonal therapy. Side effects of tamoxifen and their effects on physical, emotional and social functioning have been shown to impair the quality of life. Aim of this paper was to evaluate the side effects and level of influence on the physical, emotional and social functioning caused by tamoxifen treatment. For assessment of quality of life an own questionnaire was designed. Between January 2001 and December 2003, 136 women with breast cancer and adjuvant tamoxifen therapy were included in this study. Data of side effects, physical and mental health and patients' self-evaluation identified detrimental effects on patients' quality of life. Prevalence and severity of symptoms were not influenced by length of tamoxifen treatment. Patients were damaged in their constitution in respect to previous chemotherapy and pre-existing diseases; no influence was found by age or histopathological tumour characteristics. Our survey determines that breast cancer patients experience significant influence on quality of life by the negative impact on the physical, emotional and social functioning caused by tamoxifen treatment. Explicit attention to changes in quality of life should be considered as part of the standard care for women receiving adjuvant tamoxifen treatment. 相似文献
15.
Lazzaro Repetto Pier Giorgio Giannessi Elisabetta Campora Paolo Pronzato Antonella Vigani Cinzia Naso Italo Spinelli Pier Franco Conte Riccardo Rosso 《Breast cancer research and treatment》1996,39(2):235-238
Summary It has been demonstrated, both in breast cancer cell lines and in metastatic breast cancer patients with cutaneous lesions that could be biopsied, that treatment with interferon beta (IFN-B) can increase expression of both estrogen (ER) and progesterone receptors (PgR). To evaluate the efficacy and toxicity of the combination of IFN and tamoxifen, 33 metastatic breast cancer patients were treated with the following regimen: IFN-B, 6.0 million units intramuscularly IU 3 times a week for two consecutive weeks followed by IFN-B 6.0 million IU im 3 times a week with concomitant tamoxifen 20 mg orally daily. Patients were pre and postmenopausal with median age of 60 years, median ECOG PS of 0, either ER positive or unknown, and had not received prior hormone therapy for metastatic disease. Overall objective response was observed in 9 (27%) patients. Complete response was observed in 2 cases and partial response in 7 patients. Median duration of response was 7 months (range 2–10). A higher response rate was observed in patients with predominantly soft tissue disease (38%) compared to patients with either dominant bone (18%) or visceral lesions (17%). Toxicity was mild and reversible: low grade fever in 30% of patients and flu-like symptoms in 9% of cases. It appears that IFN-B does not improve the efficacy of tamoxifen in an unselected population of metastatic breast cancer. 相似文献
16.
Treatment of advanced breast cancer with tamoxifen: Evaluation of the dose-response relationship at two dose levels 总被引:1,自引:0,他引:1
Carsten Rose M.D. Karen Theilade M.D. Else Boesen M.D. Marianne Salimtschik M.D. Per Dombernowsky M.D. Niels Brünner M.D. Mogens Kjær M.D. Henning T. Mouridsen M.D. 《Breast cancer research and treatment》1982,2(4):395-400
Summary In order to establish the optimal dose of tamoxifen in the treatment of advanced breast cancer in postmenopausal women, a randomized trial comparing 90 mg daily with the currently recommended dose of 30 mg daily was conducted. Sixty-eight patients were treated with the high dose and 75 patients with the low dose. The rate of response was 36 and 37% (p = 0.74), respectively. The time to response, duration of response, and the time to treatment failure were also identical at the two dose levels. Only a few side effects were observed, and they were equally distributed among the two treatment groups. It is concluded that a 30 mg daily dose of tamoxifen seems to be as effective as 90 mg. 相似文献
17.
John H. Glick M.D. Richard H. Creech M.D. Susan Torri R.N. Christopher Holroyde M.D. Harvey Brodovsky M.D. Robert B. Catalano Pharm.D. Michael Varano Ph.D. 《Breast cancer research and treatment》1981,1(1):59-68
Summary Eighty-eight postmenopausal women with metastatic breast cancer, in whom estrogen receptors (ER) were positive or unknown, were treated on a controlled trial to determine the effectiveness of tamoxifen and to assess the therapeutic advantage of sequentially adding low-dose cyclophosphamide-methotrexate-5-fluorouracil (CMF) chemotherapy in tamoxifen responders. Patients with known ER negative status were not studied. After the initial 12-week treatment with tamoxifen alone, 60% of ER positive patients achieved complete or partial response as did 35% in whom ER were unknown. Response status further improved in 18% randomized to continue tamoxifen alone vs 31% in whom CMF was added to tamoxifen. There were no statistically significant differences in time to the development of progressive disease or survival between the ER positive and ER unknown patients or between the tamoxifen and tamoxifen plus CMF groups. We conclude that inability to determine ER status should not prejudice against the use of tamoxifen in postmenopausal patients with advanced breast cancer. No benefit has been demonstrated from the addition of CMF chemotherapy in tamoxifen responders.
Address for reprints: J.H. Glick, M.D., Hospital of the University of Pennsylvania, 3400 Spruce St., Philadelphia, PA 19104. 相似文献
18.
Foekens JA Ries Ch Look MP Gippner-Steppert C Klijn JG Jochum M 《British journal of cancer》2003,88(7):1084-1090
Besides a variety of other proteases, polymorphonuclear leukocyte elastase (PMN-E) is also suggested to play a role in the processes of tumour cell invasion and metastasis. Yet, there is only limited data available on the relation between the tumour level of PMN-E and prognosis in patients with primary breast cancer, and no published information exists on its relation with the efficacy of response to systemic therapy in patients with advanced breast cancer. In the present study, we have measured with enzyme-linked immunosorbent assay the levels of total PMN-E in cytosolic extracts of 463 primary breast tumours, and have correlated their levels with the rate and duration of response on first-line tamoxifen therapy (387 patients) or chemotherapy (76 patients) in patients with locally advanced and/or distant metastatic breast cancer. Furthermore, the probabilities of progression-free survival and postrelapse survival were studied in relation to the tumour levels of PMN-E. Our results show that in logistic regression analysis for response to tamoxifen treatment in patients with advanced disease, high PMN-E tumour levels were associated with a poor rate of response compared with those with low PMN-E levels (odds ratio: OR, 0.40; 95% CI, 0.22-0.73; P=0.003). After correction for the contribution of the traditional predictive factors in multivariate analysis, the tumour PMN-E status was an independent predictor of response (P=0.01). Furthermore, a high tumour PMN-E level was related with a poor progression-free survival (P<0.001) and postrelapse survival (P=0.002) in a time-dependent analysis. In contrast, the tumour level of PMN-E was not significantly related with the efficacy of response to first-line chemotherapy in patients with advanced breast cancer. Our present results suggest that PMN-E is an independent predictive marker for the efficacy of tamoxifen treatment in patients with advanced breast cancer. 相似文献
19.
PF Bruning JGM Bonfrèr E Engelsman E Hamersma-v.d. Linden M de Jong-Bakker W Nooyen 《Breast cancer research and treatment》1984,4(4):289-295
Summary In a phase II clinical trial, 38 postmenopausal women with advanced breast cancer were treated with aminoglutethimide and replacement hydrocortisone. All women had previously received up to 4 modalities of endocrine therapy. Seventeen patients had also been treated with cytostatic drugs. Twenty-five percent of the 29 evaluable patients experienced objective tumor regression, lasting from 11 to more than 18 months. In 29% the disease was stabilized for 3 to more than 15 months. Toxicity was significant, necessitating drug withdrawal in 3 patients. One patient died within 3 weeks of therapy from multiple perforated gastric ulcers. Two patients developed herpes zoster within 4 weeks of treatment. Many side effects were minor and transient. However, treatment resulted in overt primary hypothyroidism in 25% of the evaluable patients and in a strongly increased need of acenocoumarin in all 3 patients on anticoagulant therapy. 相似文献
20.